Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL

Simon Husby; Cecilie Bæch-Laursen; Christian W. Eskelund; Francesco Favero; Jakob Schmidt Jespersen; Martin Hutchings; Lone Bredo Pedersen; Carsten U. Niemann; Joachim Weischenfeldt; Riikka Räty; Thomas Stauffer Larsen; Arne Kolstad; Mats Jerkeman; Kirsten Grønbæk

doi:10.1038/s41375-022-01725-8

Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL

Simon Husby^*, Cecilie Bæch-Laursen, Christian W. Eskelund, Francesco Favero, Jakob Schmidt Jespersen, Martin Hutchings, Lone Bredo Pedersen, Carsten U. Niemann, Joachim Weischenfeldt, Riikka Räty, Thomas Stauffer Larsen, Arne Kolstad, Mats Jerkeman, Kirsten Grønbæk

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

4 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Leukemia
Vol/bind	36
Sider (fra-til)	2912-2916
ISSN	0887-6924
DOI	https://doi.org/10.1038/s41375-022-01725-8
Status	Udgivet - 2022

Bibliografisk note

Funding Information:
The research was supported by Rigshospitalets Research Foundation and the Novo Nordisk Foundation (Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant NNF17CC0027852). The project is part of the Danish Research Center for Precision Medicine in Blood Cancers funded by the Danish Cancer Society grant no. R223-A13071 and Greater Copenhagen Health Science Partners. The clinical trial was investigator-initiated and supported by Janssen and Celgene.

Adgang til dokumentet

10.1038/s41375-022-01725-8

Citationsformater

Husby, S., Bæch-Laursen, C., Eskelund, C. W., Favero, F., Jespersen, J. S., Hutchings, M., Pedersen, L. B., Niemann, C. U., Weischenfeldt, J., Räty, R., Larsen, T. S., Kolstad, A., Jerkeman, M., & Grønbæk, K. (2022). Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL. Leukemia, 36, 2912-2916. https://doi.org/10.1038/s41375-022-01725-8

Husby, S, Bæch-Laursen, C, Eskelund, CW, Favero, F , Jespersen, JS, Hutchings, M, Pedersen, LB, Niemann, CU , Weischenfeldt, J, Räty, R, Larsen, TS, Kolstad, A, Jerkeman, M & Grønbæk, K 2022, 'Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL', Leukemia, bind 36, s. 2912-2916. https://doi.org/10.1038/s41375-022-01725-8

@article{26f71fe7c9f546e4a2ef5bd4d9e53baa,

title = "Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL",

author = "Simon Husby and Cecilie B{\ae}ch-Laursen and Eskelund, {Christian W.} and Francesco Favero and Jespersen, {Jakob Schmidt} and Martin Hutchings and Pedersen, {Lone Bredo} and Niemann, {Carsten U.} and Joachim Weischenfeldt and Riikka R{\"a}ty and Larsen, {Thomas Stauffer} and Arne Kolstad and Mats Jerkeman and Kirsten Gr{\o}nb{\ae}k",

note = "Funding Information: The research was supported by Rigshospitalets Research Foundation and the Novo Nordisk Foundation (Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant NNF17CC0027852). The project is part of the Danish Research Center for Precision Medicine in Blood Cancers funded by the Danish Cancer Society grant no. R223-A13071 and Greater Copenhagen Health Science Partners. The clinical trial was investigator-initiated and supported by Janssen and Celgene. ",

year = "2022",

doi = "10.1038/s41375-022-01725-8",

language = "English",

volume = "36",

pages = "2912--2916",

journal = "Leukemia",

issn = "0887-6924",

publisher = "nature publishing group",

}

TY - JOUR

T1 - Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL

AU - Husby, Simon

AU - Bæch-Laursen, Cecilie

AU - Eskelund, Christian W.

AU - Favero, Francesco

AU - Jespersen, Jakob Schmidt

AU - Hutchings, Martin

AU - Pedersen, Lone Bredo

AU - Niemann, Carsten U.

AU - Weischenfeldt, Joachim

AU - Räty, Riikka

AU - Larsen, Thomas Stauffer

AU - Kolstad, Arne

AU - Jerkeman, Mats

AU - Grønbæk, Kirsten

N1 - Funding Information: The research was supported by Rigshospitalets Research Foundation and the Novo Nordisk Foundation (Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant NNF17CC0027852). The project is part of the Danish Research Center for Precision Medicine in Blood Cancers funded by the Danish Cancer Society grant no. R223-A13071 and Greater Copenhagen Health Science Partners. The clinical trial was investigator-initiated and supported by Janssen and Celgene.

PY - 2022

Y1 - 2022

U2 - 10.1038/s41375-022-01725-8

DO - 10.1038/s41375-022-01725-8

M3 - Journal article

C2 - 36274067

AN - SCOPUS:85140313538

SN - 0887-6924

VL - 36

SP - 2912

EP - 2916

JO - Leukemia

JF - Leukemia

ER -